[6-K] Wearable Devices Ltd. Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Wearable Devices Ltd. (WLDS) entered a Securities Purchase Agreement for a registered direct offering to a single institutional investor, selling 655,000 ordinary shares at $2.67 per share and pre‑funded warrants for up to 575,000 shares at $2.6699 each, each with an accompanying ordinary warrant.

The Pre‑Funded Warrants are exercisable immediately at $0.0001 per share and include a 9.99% beneficial ownership cap. In a concurrent private placement, the Company will issue ordinary warrants for up to 1,230,000 shares with a $2.67 exercise price, exercisable upon shareholder approval and expiring five years after approval. The transaction uses an effective Form F‑3 and an October 29, 2025 prospectus supplement.

The Company agreed to 60‑day restrictions on additional issuances and variable‑rate transactions, subject to specified exceptions. Existing September 2025 investor warrants for 1,000,000 shares at $4.00 and 670,000 shares at $6.00 will have their exercise prices reduced to $2.67, subject to shareholder approval, and will expire five years after approval.

Insights

Capital markets analyst

WLDS prices equity and warrant package; dilution overhang depends on exercises.

WLDS structured a registered direct sale of shares and pre‑funded warrants, paired with privately placed warrants. Immediate exercisability of the pre‑funded warrants at $0.0001 per share and a 9.99% cap addresses ownership limits while providing near‑cash equivalence at purchase.

The private placement warrants cover up to 1,230,000 shares at $2.67, but require shareholder approval before exercisability, adding a gating step. A 60‑day covenant limits further issuance and variable‑rate deals, reducing near‑term supply risk per the agreement’s exceptions.

Amending prior warrants (1,000,000 at $4.00 and 670,000 at $6.00) down to $2.67 aligns strikes with the new pricing but increases potential exercises if approval is obtained. Actual impact hinges on holder decisions and the shareholder vote.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of October 2025 (Report No. 2)

Commission File Number: 001-41502

WEARABLE DEVICES Ltd.

(Translation of registrant’s name into English)

5 Ha-Tnufa Street

Yokne-am Illit, Israel 2066736

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒      Form 40-F ☐

CONTENTS

On October 29, 2025, Wearable Devices Ltd. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a single institutional investor (the “Purchaser”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Purchaser (the “Registered Direct Offering”): (i) 655,000 of the Company’s ordinary shares, no par value per share (the “Ordinary Shares”), at an offering price of $2.67 per share, together with an accompanying Ordinary Warrant (as defined below); and (ii) pre-funded warrants to acquire up to 575,000 Ordinary Shares (the “Pre-Funded Warrants”) at an offering price of $2.6699 per Pre-Funded Warrant, together with an accompanying Ordinary Warrant.

The Pre-Funded Warrants were sold to the Purchaser, whose purchase of Ordinary Shares in the Registered Direct Offering would otherwise have resulted in the Purchaser, together with its affiliates and certain related parties, beneficially owning more than 9.99% of the outstanding share capital of the Company following the consummation of the Registered Direct Offering. Each Pre-Funded Warrant represents the right to purchase one Ordinary Share at an exercise price of $0.0001 per share. The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until the Pre-Funded Warrants are exercised in full (subject to the beneficial ownership limitation described above).

The Purchase Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company, other obligations of the parties, and termination provisions.

In addition, unless waived by the Purchaser, the Company agreed that for a period of sixty (60) days from the closing date of the Registered Direct Offering, it will not: (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any Ordinary Shares or equivalent securities; or (ii) file any registration statement or amendment or supplement thereto, other than (a) the Prospectus Supplement (as defined below), (b) registration statement on Form S-8, (c) the resale registration statement to be filed pursuant to the Company’s obligations under the Securities Purchase Agreement dated September 11, 2025, and the Securities Purchase agreement dated September 12, 2025 (d) any amendment to, or a new filing of, a registration statement on Form F-3, including for the purposes of selling Ordinary Shares in the ATM Facility (as the term is defined in the Purchase Agreement), (e) any amendment or supplement to any registration statement that the Company currently has on file on EDGAR and which has been declared effective prior to the date of the Purchase Agreement or (f) in connection with the registration for resale of the ordinary shares underlying the Ordinary Warrants issued in the concurrent private placement, as described below). In addition, unless waived by the Purchaser, the Company agreed that it will not conduct any sales of Ordinary Shares or equivalent securities involving a variable rate transaction (as defined in the Purchase Agreement) for a period of sixty (60) days, subject to certain exceptions as described in the Purchase Agreement.

The Ordinary Shares and Pre-Funded Warrants were offered by the Company pursuant to a registration statement on Form F-3 (File No. 333-274841) (the “Registration Statement”), previously filed and declared effective by the Securities and Exchange Commission (the “Commission”) on October 18, 2023, the base prospectus filed as part of the Registration Statement, and the prospectus supplement dated October 29, 2025 (the “Prospectus Supplement”).

In a concurrent private placement (together with the Registered Direct Offering, the “Offering”), pursuant to the Purchase Agreement, the Company agreed to issue and sell to the Purchaser ordinary warrants to acquire up to 1,230,000 Ordinary Shares (the “Ordinary Warrants” and, together with the Ordinary Shares and the Pre-Funded Warrants, the “Securities”) at an exercise price of $2.67 per share. The Ordinary Warrants will be exercisable immediately upon shareholder approval of the issuance of the Ordinary Warrants is obtained and will expire five years from the date shareholder approval is obtained. The Ordinary Warrants and the Ordinary Shares issuable upon the exercise of the Ordinary Warrants are not being registered under the Securities Act of 1933, as amended (the “Securities Act”), were not offered pursuant to the Registration Statement and Prospectus Supplement and were offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and/or Regulation D promulgated thereunder. The Purchase Agreement requires the Company to file a registration statement on Form F-3 (or any other available form), as soon as practicable (and in any event within 15 calendar days of the date of the shareholder approval), to register the Ordinary Shares issuable upon exercise of the Ordinary Warrants and to use commercially reasonable efforts to cause such registration statement to become effective within 60 days, or within 90 days of the filing of the registration statement in the event of a full review by the Commission, with a limited extension of the effectiveness date to take into account the current shutdown of certain departments and agencies of the U.S. government, and to keep such registration statement effective as provided in the Purchase Agreement.

In connection with the Offering, the Company also entered into an agreement to amend existing warrants (the “Warrant Amendment Agreement”) that were previously issued in September 2025 to the investor participating in the Offering. Such existing warrants originally entitled the investor to purchase up to (i) 1,000,000 ordinary shares of the Company, with an exercise price of $4.00 per share and up to (ii) 670,000 ordinary shares of the Company, with an exercise price of $6.00 per share. Such existing warrants have been amended to reduce the exercise price to $2.67 per share. The warrant amendment is also subject to shareholder approval, and the warrants shall expire five years from the date shareholder approval is obtained.

1

The foregoing summaries of the Purchase Agreement, the Ordinary Warrants, the Pre-Funded Warrants, and the Warrant Amendment Agreement do not purport to be complete and are subject to, and qualified in their entirety by, such documents filed as Exhibits 10.1, 4.1, 4.2, and 4.3, respectively, hereto and incorporated by reference herein. A copy of the press release related to the Offering entitled “Wearable Devices Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules” is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

This Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) shall not constitute an offer to sell any securities or a solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Copies of the opinions of Sullivan & Worcester Tel Aviv (Har-Even & Co.) and Sullivan & Worcester LLP relating to the legality of the issuance and sale of the Ordinary Shares and the Pre-Funded Warrants, respectively, are filed as Exhibits 5.1 and 5.2 hereto, respectively.

This Report is incorporated by reference into the registration statements on Form S-8 (File Nos. 333-290148, 333-284010, 333-269869 and 333-274343) and on Form F-3 (File Nos. 333-274841,333-287247 and 333-291100) of the Company, filed with the Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Forward-Looking Statements:

This Report contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. For example, the Company is using forward-looking statements when it discusses the closing of the Offering and issuance of warrants that are subject to shareholder approvals. The Offering is subject to closing conditions and the Company’s shareholders may not approve the warrants that require shareholder approval. All statements other than statements of historical facts included in this Report are forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company’s current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include the risks and uncertainties described in the Company’s annual report on Form 20-F for the year ended December 31, 2024, filed with the Commission on March 20, 2025, and the Company’s other filings with the Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

2

EXHIBIT INDEX

Exhibit No.		Description
4.1		Form of Ordinary Warrant.
4.2		Form of Pre-Funded Warrant.
4.3		Form of Warrant Amendment Agreement
5.1		Opinion of Sullivan & Worcester Tel Aviv (Har-Even & Co.)
5.2		Opinion of Sullivan & Worcester LLP
10.1		Form of Securities Purchase Agreement, dated as of October 29, 2025, by and between the Company and the purchaser party thereto.
23.1		Consent of Sullivan & Worcester Tel Aviv (Har-Even & Co.) (included in Exhibit 5.1).
23.2		Consent of Sullivan & Worcester LLP (included in Exhibit 5.2).
99.1		Press Release issued by Wearable Devices Ltd., dated October 30, 2025, titled “Wearable Devices Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules.”

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Wearable Devices Ltd.
Date: October 31, 2025	By:	/s/ Asher Dahan
		Asher Dahan
		Chief Executive Officer

4

FAQ

What did WLDS announce in this 6-K?

A registered direct offering of 655,000 ordinary shares at $2.67 and pre‑funded warrants for up to 575,000 shares at $2.6699, each with an accompanying ordinary warrant.

What are the key terms of WLDS pre-funded warrants?

Each pre‑funded warrant is exercisable immediately at $0.0001 per share and includes a 9.99% beneficial ownership limitation.

What is included in the concurrent private placement for WLDS?

Ordinary warrants to acquire up to 1,230,000 shares at an exercise price of $2.67, exercisable upon shareholder approval and expiring five years after approval.

Are the private placement warrants registered?

No. They were offered under Section 4(a)(2)/Reg D and are not registered under the Securities Act.

What lock-up or issuance restrictions did WLDS agree to?

For 60 days, the Company agreed to limits on issuing equity or variable‑rate transactions, with specified exceptions.

Did WLDS amend existing warrants?

Yes. Warrants for 1,000,000 shares at $4.00 and 670,000 shares at $6.00 will have exercise prices reduced to $2.67, subject to shareholder approval.

Which registration statement covers the offering?

Form F‑3 (File No. 333-274841), declared effective on October 18, 2023, with a prospectus supplement dated October 29, 2025.